Intech Investment Management LLC Acquires 22,146 Shares of Collegium Pharmaceutical, Inc. $COLL

Intech Investment Management LLC raised its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 25.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 108,855 shares of the specialty pharmaceutical company’s stock after purchasing an additional 22,146 shares during the quarter. Intech Investment Management LLC’s holdings in Collegium Pharmaceutical were worth $5,040,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Rubric Capital Management LP raised its position in Collegium Pharmaceutical by 5.3% in the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after purchasing an additional 157,743 shares during the last quarter. Vanguard Group Inc. raised its position in Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares during the last quarter. Principal Financial Group Inc. raised its position in Collegium Pharmaceutical by 0.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock valued at $60,823,000 after purchasing an additional 3,891 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after purchasing an additional 518,721 shares during the last quarter. Finally, Millennium Management LLC raised its position in Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after purchasing an additional 461,914 shares during the last quarter.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total value of $488,041.92. Following the transaction, the executive vice president directly owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the transaction, the executive vice president directly owned 71,770 shares in the company, valued at approximately $2,900,225.70. The trade was a 41.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on COLL. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. Finally, Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $33.61 on Monday. Collegium Pharmaceutical, Inc. has a 52-week low of $28.74 and a 52-week high of $50.79. The stock has a market cap of $1.09 billion, a PE ratio of 16.48 and a beta of 0.75. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The firm’s 50 day moving average price is $34.12 and its two-hundred day moving average price is $41.37.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. During the same period last year, the firm earned $1.49 earnings per share. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. As a group, analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.